Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Surrozen
Research
The Column Group biotech taps Surrozen to target lung fibrosis
TCGFB is paying Surrozen up to $6 million for antibodies that target transforming growth factor beta, a major contributor to lung diseases.
Darren Incorvaia
Nov 4, 2024 11:14am
Surrozen's Wnt mimetic antibody works in mice with lung fibrosis
Apr 4, 2024 4:30am
Surrozen stops IBD program due to dose concerns and competition
Jan 18, 2024 9:55am
Surrozen culls 2 research programs as cash preservation persists
Aug 10, 2023 10:30am
Surrozen halts trial as liver enzyme elevations crop up
Nov 15, 2022 7:30am
Boehringer pledges $599M for Surrozen's eye disease asset
Oct 6, 2022 11:00am
